Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical innovation company accelerating high-impact technologies ...

NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact ...

A new study published in the New England Journal of Medicine showed that improvements in symptoms and quality of life were ...

The RHEIA trial studied women with severe aortic stenosis and found that participants preferred transcatheter aortic valve replacement over surgical valve replacement.

A new study published in the Journal of American Medical Association showed that the upper-extremity route for secondary ...

Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to ...

TTVR also led to "near elimination" of the TR, as 99.1% of people had moderate or less TR (and 95.3% mild or less) at the ...

Jenscare Scientific Co., Ltd. ('Jenscare' or the 'Company') (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR ...

Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement ... 5.3% of the control group (P=0.003); new permanent pacemakers were implanted in 17.4% and 2.3% ...

Sandra Lesenfants, senior vice president of Abbott’s Structural Heart business, shares an update on MitraClip, TriClip, and ...

TCT 943: Durable Valve Prosthesis Performance and Sustained Symptom Relief: 2-Year Outcomes Following Transseptal Transcatheter Mitral Valve Replacement in the HighLife TSMVR Feasibility Study Receive ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...